明德生物(002932.SZ)：拟增资并收购湖南蓝怡股权

Group 1 - The company Mingde Bio (002932.SZ) has approved a proposal to increase capital and acquire a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd. for 35.701 million yuan [1] - Following the acquisition, Hunan Lanyi will become a subsidiary of Mingde Bio and will be included in the company's consolidated financial statements [1] - The acquisition is contingent upon Hunan Lanyi meeting certain operational conditions from 2026 to 2028 as outlined in the acquisition agreement [1] Group 2 - Hunan Lanyi, established in September 2020, focuses on the research, development, and production of IVD instruments and reagents, and has been recognized as a national high-tech enterprise [2] - The company specializes in the detection of glycosylated hemoglobin using high-performance liquid chromatography (HPLC) and has developed the AH-600 series as a core product [2] - Despite current losses due to high initial R&D investments and strategic market expenditures, the demand for glycosylated hemoglobin testing is expected to grow, particularly with its inclusion in free health check-ups for seniors over 65 [2]